No Data
Earnings Troubles May Signal Larger Issues for Henan Taloph Pharmaceutical StockLtd (SHSE:600222) Shareholders
Tailong Pharmaceutical: Tailong Pharmaceutical Report for the First Quarter of 2025
Tailong Pharmaceutical\'s 2025 First Quarter Report
Henan Taloph Pharmaceutical Stock (600222.SH) reported a net income of 1.53 million yuan in the first quarter, a 92.8% year-on-year decline.
Gelonghui, April 29th丨Henan Taloph Pharmaceutical Stock (600222.SH) announced its first-quarter report for 2025, with revenue of 0.323 billion yuan, a year-on-year decrease of 35.2%; Net income attributable to shareholders was 1.53 million yuan, a year-on-year decrease of 92.8%; Net income attributable to shareholders excluding non-recurring items was 0.46 million yuan, a year-on-year decrease of 97.6%.
Tailong Pharmaceutical: Summary of Tailong Pharmaceutical\'s 2024 Annual Report
Tailong Pharmaceutical: Tailong Pharmaceutical 2024 Annual Report
Why Investors Shouldn't Be Surprised By Henan Taloph Pharmaceutical Stock Co.,Ltd's (SHSE:600222) 30% Share Price Plunge
